Compare REX AI Equity Premium Income ETF (AIPI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Novo Nordisk A/S — how do they compare? REX AI Equity Premium Income ETF trades at $37.45, while Novo Nordisk A/S trades at $46.46 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while REX AI Equity Premium Income ETF pays none. Which is the better fit depends on your goals.
| AIPI | NVO | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $63.98 |
52-Week Low | $32.45 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.42, up 0.21% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock exhibits a high distribution yield strategy, paying weekly dividends, with recent payouts ranging from $0.23 to $0.26. Support and resistance are tightly clustered around $37-$38, indicating potential volatility. Recent news highlights the fund's transition to weekly distributions and questions about sustainability amid AI market dynamics.
The outlook for AIPI hinges on its ability to sustain high yields through its option-writing strategy, though structural risks and NAV erosion concerns persist. Investment opportunity lies in income generation, but risks include dependency on AI sector performance and capped upside. Analyst sentiment is mixed, with some caution over long-term viability.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
